Chimerix Inc

Chimerix — J.P. Morgan Healthcare Conference 2018

25 slides from Chimerix's conference presentation, Jan 10, 2018

  1. Slide 1: J.P. Morgan Healthcare Conference

    Slide 1: J.P. Morgan Healthcare Conference

    J.P. MORGAN HEALTHCARE CONFERENCE M. MICHELLE BERREY, MD, MPH PRESIDENT AND CEO JANUARY 2018

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility that th

  3. Slide 3: Why Are We Excited About 2018?

    Slide 3: Why Are We Excited About 2018?

    3 Why Are We Excited About 2018?  AdAPT trial of short-course oral BCV for adenovirus enrolling and data expected in 2019; if positive, data should support first regulatory approval  Lack of GI side-effects with multiple doses of IV BCV supports progression to Phase 2 patient studies in 2018, lead

  4. Slide 4: Data-Rich 2018 and 2019 Ahead of Regulatory Decisions

    Slide 4: Data-Rich 2018 and 2019 Ahead of Regulatory Decisions

    4 Data-Rich 2018 and 2019 Ahead of Regulatory Decisions Oral BCV Adenovirus  Enrolling AdAPT  AdVance Data  Enrolling AdAPT Adult AdAPT Data Smallpox  Pivotal mouse study  Pivotal mouse study  Supportive rabbit study  MAA submission  NDA submission IV BCV Adenovirus and CMV  Initiate Phase

  5. Slide 5: CMRX: Developing Solutions for Immunocompromised Patients

    Slide 5: CMRX: Developing Solutions for Immunocompromised Patients

    5 CMRX: Developing Solutions for Immunocompromised Patients  Experienced and committed management team with successful track records developing significant antiviral drugs and first-in-indication commercial launches  Lead compound brincidofovir has broad-spectrum antiviral activity – Short-course

  6. Slide 6: Brincidofovir: Broad Spectrum Antiviral For dsDNA Viruses

    Slide 6: Brincidofovir: Broad Spectrum Antiviral For dsDNA Viruses

    6 Brincidofovir: Broad Spectrum Antiviral For dsDNA Viruses Viral Family Virus BCV Cidofovir Maribavir Letermovir Ganciclovir* Foscarnet Acyclovir Herpes Cytomegalovirus 0.001 0.4 0.31 0.005 3.8 50-800 >200 Epstein-Barr Virus 0.03 65.6 0.63 >10 0.9 <500 6.2 Human Herpesvirus 6 0.003 2.7 Inactive >10

  7. Slide 7: AdAPT Now Enrolling – Data Expected in 2019

    Slide 7: AdAPT Now Enrolling – Data Expected in 2019

    7 AdAPT Now Enrolling – Data Expected in 2019 2017 2018 2019 2020 AdAPT DATA Oral BCV for AdV All timelines are estimated AdAPT Adult  Study being conducted in US, UK and EU  Short-course oral treatment for acute life-threatening adenovirus infections – Potent antiviral with high barrier to resist

  8. Slide 8: AdAPT: Adenovirus after Allogeneic Pediatric Transplantation

    Slide 8: AdAPT: Adenovirus after Allogeneic Pediatric Transplantation

    Follow up Period Potential Treatment Period Potential Treatment Period 8 AdAPT: Adenovirus after Allogeneic Pediatric Transplantation  Open label, comparative study of oral BCV vs. standard of care (SoC) in AdV viremia – Pediatric T-cell depleted allo-HCT recipients during first 100 days of HCT  S

  9. Slide 9: Maximizing the Probability of Success for AdAPT

    Slide 9: Maximizing the Probability of Success for AdAPT

    9 Maximizing the Probability of Success for AdAPT  Study design incorporates key learnings for oral brincidofovir: – Includes highest risk patients: pediatric recipients of T-cell depleted HCT prior to immune reconstitution – Short-course oral BCV therapy begun within the first three weeks of adeno

  10. Slide 10: Rapid Antiviral Effect of Oral Brincidofovir vs Local SOC

    Slide 10: Rapid Antiviral Effect of Oral Brincidofovir vs Local SOC

    Rapid Antiviral Effect of Oral Brincidofovir vs Local SOC* Oral BCV from AdVise 3 yr old pt 41 days post-TCD HCT Local Standard of Care (SoC) from AdVance 2 yr old pt 19 days post-HCT 21 mo, Campath, 19d post HCT 4 2 8 12 0 16 WEEK -4 0 -4 4 2 8 12 16 WEEK  Detection of AdV in the blood after trans

  11. Slide 11: Regulatory Acceptance of AdV Viral Load as a Surrogate Endpoint

    Slide 11: Regulatory Acceptance of AdV Viral Load as a Surrogate Endpoint

    11 Regulatory Acceptance of AdV Viral Load as a Surrogate Endpoint for Pivotal Studies  AdAPT was designed with European regulators; positive data should support full or conditional approval  FDA has recently announced CMV viremia as an acceptable surrogate endpoint for pivotal CMV studies; viremi

  12. Slide 12: IV BCV: Fulfilling the Potential of Brincidofovir

    Slide 12: IV BCV: Fulfilling the Potential of Brincidofovir

    Early development work shows great promise for the IV formulation 12 IV BCV: Fulfilling the Potential of Brincidofovir IV BCV delivers uniform exposure to key organs IV BCV delivers more drug to difficult-to-reach compartments, especially the brain IV BCV profile may allow for both treatment and pre

  13. Slide 13: IV BCV: Multiple-Ascending Dose Study Demonstrates Improved GI Tolerability

    Slide 13: IV BCV: Multiple-Ascending Dose Study Demonstrates Improved GI Tolerability

    13 IV BCV: Multiple-Ascending Dose Study Demonstrates Improved GI Tolerability  Multiple Ascending Dose (MAD) Study Design: – IV BCV 10 mg twice-weekly (BIW), 20 mg once-weekly (QW) for 4 doses – No dose-limiting clinical adverse events – No diarrhea with IV BCV 10 mg twice-weekly • IV BCV 10 mg pr

  14. Slide 14: Building Full Potential Value for Oral and IV Brincidofovir – Land and Expand

    Slide 14: Building Full Potential Value for Oral and IV Brincidofovir – Land and Expand

    Multiviral Protection in Peds and Adult Allo-HCT BKV Treatment in Allo-HCT and SOT Other Uses of IV BCV in DNA Viral Infections 14 Building Full Potential Value for Oral and IV Brincidofovir – “Land and Expand” Pediatric & Adult Allo-HCT Recipients Treatment Pediatric & Adult Auto HCT and SOT Recipi

  15. Slide 15: Anticipated Brincidofovir Milestones and Regulatory Decisions

    Slide 15: Anticipated Brincidofovir Milestones and Regulatory Decisions

    15 Anticipated Brincidofovir Milestones and Regulatory Decisions  Phase 2 IV BCV data to support dose-selection for MVP pivotal trial  IV BCV offers the promise of longer term dosing with improved tolerability 2017 2018 2022 MVP DATA 2019 2020 IV BCV for Multi-Viral Prevention IV BCV SAD IV BCV MA

  16. Slide 16: Brincidofovir: Oral Antiviral With Demonstrated Activity Against Smallpox

    Slide 16: Brincidofovir: Oral Antiviral With Demonstrated Activity Against Smallpox

    16 Brincidofovir: Oral Antiviral With Demonstrated Activity Against Smallpox Oral BCV has demonstrated survival benefit in two animal models of fatal orthopoxvirus infections:  Rabbitpox virus model replicates human smallpox pathophysiology: asymptomatic infection, illness, and death – 100% surviva

  17. Slide 17: Smallpox: Highest Bioweapon Threat

    Slide 17: Smallpox: Highest Bioweapon Threat

    Smallpox: Highest Bioweapon Threat 17 “The next epidemic could originate on the computer screen of a terrorist intent on using genetic engineering to create a synthetic version of the smallpox virus...” - Bill Gates, Munich, April 2017

  18. Slide 18: UN Bioweapons Conference Confirms Global Concern

    Slide 18: UN Bioweapons Conference Confirms Global Concern

    UN Bioweapons Conference Confirms Global Concern  Chimerix sponsored a smallpox symposium in December 2017 at UN Biological Weapons Convention in Geneva – Threats from synthetic biology, undeclared smallpox stockpiles – Role of antivirals as medical countermeasures  Interest level exceeded expecta

  19. Slide 19: Expedited EU Submission Supported for Brincidofovir

    Slide 19: Expedited EU Submission Supported for Brincidofovir

    19 Expedited EU Submission Supported for Brincidofovir  EMA marketing approval generally precedes procurement discussions in EU – Marketing Approval in EU can be cross-referenced for international procurement contracts outside the EU  Formal Scientific Advice was requested from the CHMP regarding

  20. Slide 20: Second Animal Model of Orthopoxvirus for US Submission

    Slide 20: Second Animal Model of Orthopoxvirus for US Submission

    20 Second Animal Model of Orthopoxvirus for US Submission 2017 2018 2019 2020 Oral BCV for smallpox Mouse Efficacy Study All timelines are estimated DATA Supportive Rabbit Study  Plan to initiate pivotal mouse study and supportive rabbit study in 2018  Data could support filing in US for smallpox

  21. Slide 21: CMX521: The First Specific Antiviral for Norovirus

    Slide 21: CMX521: The First Specific Antiviral for Norovirus

    CMX521: The First Specific Antiviral for Norovirus  As a nucleoside selected from the Chimerix Chemical Library, CMX521: – targets the polymerase, an enzyme essential for viral replication – targets a portion of the virus that remains consistent across diverse strains – has demonstrated in vitro an

  22. Slide 22: Treatment Target is the Gut Epithelia

    Slide 22: Treatment Target is the Gut Epithelia

    22 Treatment Target is the Gut Epithelia Norovirus replicates in epithelium of the gut May need to target only cells represented by yellow highlight Without CMX521 CMX521 3 hrs before virus CMX521 at time of virus  In vitro, efficacious levels of active antiviral reached at 2-4 hours after drug exp

  23. Slide 23: Two Distinct Norovirus Opportunities

    Slide 23: Two Distinct Norovirus Opportunities

    Two Distinct Norovirus Opportunities  Treatment of Chronic Norovirus – Increasingly recognized in immunocompromised patients: • Stem cell transplant recipients • Solid organ transplant recipients • Other immunocompromised patients including those on biologics – Asymptomatic shedders who increase pu

  24. Slide 24: CMRX: Building A Pipeline of Solutions for Patients at Risk of Serious Viral Infections

    Slide 24: CMRX: Building A Pipeline of Solutions for Patients at Risk of Serious Viral Infections

    24 CMRX: Building A Pipeline of Solutions for Patients at Risk of Serious Viral Infections 2017 2018 2021 MVP / pivotal DATA 2019 2020 IV BCV for Multi-Viral Prevention 2022 AdAPT DATA Oral BCV for AdV CMX521 SAD/MAD CMX521 POC CMX521 Treatment of Norovirus CMX521 Prevention of Norovirus Outbreaks D

  25. Slide 25: CMRX: Four Active Clinical Programs in 2018

    Slide 25: CMRX: Four Active Clinical Programs in 2018

    25 CMRX: Four Active Clinical Programs in 2018 Program Indication Pre-clinical Phase 1 Phase 2 Phase 3 Status Anticipated Approval Short-course Oral BCV AdV Treatment AdAPT enrolling 2021 Smallpox Animal Rule models progressing 2020 IV BCV Multi-viral Prevention Ph 2 in patients 2018 2022 CMX521 Nor

Source: SEC EDGAR · 8-K filed Jan 10, 2018

More decks from Chimerix Inc